175 related articles for article (PubMed ID: 38571885)
21. HAF mediates the evasive resistance of anti-angiogenesis TKI through disrupting HIF-1α and HIF-2α balance in renal cell carcinoma.
Lai XM; Liu SY; Tsai YT; Sun GH; Chang SY; Huang SM; Cha TL
Oncotarget; 2017 Jul; 8(30):49713-49724. PubMed ID: 28572533
[TBL] [Abstract][Full Text] [Related]
22. Prolyl hydroxylase 2 dependent and Von-Hippel-Lindau independent degradation of Hypoxia-inducible factor 1 and 2 alpha by selenium in clear cell renal cell carcinoma leads to tumor growth inhibition.
Chintala S; Najrana T; Toth K; Cao S; Durrani FA; Pili R; Rustum YM
BMC Cancer; 2012 Jul; 12():293. PubMed ID: 22804960
[TBL] [Abstract][Full Text] [Related]
23. Expression of hypoxia inducible factor-1alpha and 2alpha in genetically distinct early renal cortical tumors.
Kim CM; Vocke C; Torres-Cabala C; Yang Y; Schmidt L; Walther M; Linehan WM
J Urol; 2006 May; 175(5):1908-14. PubMed ID: 16600797
[TBL] [Abstract][Full Text] [Related]
24. Renal cancer cells lacking hypoxia inducible factor (HIF)-1alpha expression maintain vascular endothelial growth factor expression through HIF-2alpha.
Shinojima T; Oya M; Takayanagi A; Mizuno R; Shimizu N; Murai M
Carcinogenesis; 2007 Mar; 28(3):529-36. PubMed ID: 16920734
[TBL] [Abstract][Full Text] [Related]
25. Follistatin-like protein 1 plays a tumor suppressor role in clear-cell renal cell carcinoma.
Liu Y; Tan X; Liu W; Chen X; Hou X; Shen D; Ding Y; Yin J; Wang L; Zhang H; Yu Y; Hou J; Thompson TC; Cao G
Chin J Cancer; 2018 Jan; 37(1):2. PubMed ID: 29357946
[TBL] [Abstract][Full Text] [Related]
26. Down-regulation of CD74 inhibits growth and invasion in clear cell renal cell carcinoma through HIF-1α pathway.
Ji SQ; Su XL; Cheng WL; Zhang HJ; Zhao YQ; Han ZX
Urol Oncol; 2014 Feb; 32(2):153-61. PubMed ID: 23273913
[TBL] [Abstract][Full Text] [Related]
27. PTEN suppression of YY1 induces HIF-2 activity in von-Hippel-Lindau-null renal-cell carcinoma.
Petrella BL; Brinckerhoff CE
Cancer Biol Ther; 2009 Jul; 8(14):1389-401. PubMed ID: 19483472
[TBL] [Abstract][Full Text] [Related]
28. Low nuclear expression of HIF-hydroxylases PHD2/EGLN1 and PHD3/EGLN3 are associated with poor recurrence-free survival in clear cell renal cell carcinoma.
Luomala L; Mattila K; Vainio P; Nisén H; Pellinen T; Lohi J; Laajala TD; Järvinen P; Koskenniemi AR; Jaakkola P; Mirtti T
Cancer Med; 2024 Feb; 13(3):e6998. PubMed ID: 38400673
[TBL] [Abstract][Full Text] [Related]
29. Association of hypoxia-inducible factors 1alpha and 2alpha with activated angiogenic pathways and prognosis in patients with endometrial carcinoma.
Sivridis E; Giatromanolaki A; Gatter KC; Harris AL; Koukourakis MI;
Cancer; 2002 Sep; 95(5):1055-63. PubMed ID: 12209691
[TBL] [Abstract][Full Text] [Related]
30. Expression of nuclear FIH independently predicts overall survival of clear cell renal cell carcinoma patients.
Kroeze SG; Vermaat JS; van Brussel A; van Melick HH; Voest EE; Jonges TG; van Diest PJ; Hinrichs J; Bosch JL; Jans JJ
Eur J Cancer; 2010 Dec; 46(18):3375-82. PubMed ID: 20709525
[TBL] [Abstract][Full Text] [Related]
31. Hypoxia inducible factor-1alpha correlates with vascular endothelial growth factor A and C indicating worse prognosis in clear cell renal cell carcinoma.
Dorević G; Matusan-Ilijas K; Babarović E; Hadzisejdić I; Grahovac M; Grahovac B; Jonjić N
J Exp Clin Cancer Res; 2009 Mar; 28(1):40. PubMed ID: 19302703
[TBL] [Abstract][Full Text] [Related]
32. Epigenetic regulation of HIF-1α in renal cancer cells involves HIF-1α/2α binding to a reverse hypoxia-response element.
Xu J; Wang B; Xu Y; Sun L; Tian W; Shukla D; Barod R; Grillari J; Grillari-Voglauer R; Maxwell PH; Esteban MA
Oncogene; 2012 Feb; 31(8):1065-72. PubMed ID: 21841824
[TBL] [Abstract][Full Text] [Related]
33. The role of aberrant VHL/HIF pathway elements in predicting clinical outcome to pazopanib therapy in patients with metastatic clear-cell renal cell carcinoma.
Choueiri TK; Fay AP; Gagnon R; Lin Y; Bahamon B; Brown V; Rosenberg JE; Hutson TE; Baker-Neblett KL; Carpenter C; Liu Y; Pandite L; Signoretti S
Clin Cancer Res; 2013 Sep; 19(18):5218-26. PubMed ID: 23881929
[TBL] [Abstract][Full Text] [Related]
34. Analysis of various potential prognostic markers and survival data in clear cell renal cell carcinoma.
Ebru T; Fulya OP; Hakan A; Vuslat YC; Necdet S; Nuray C; Filiz O
Int Braz J Urol; 2017; 43(3):440-454. PubMed ID: 27583351
[TBL] [Abstract][Full Text] [Related]
35. The correlation of expression levels of HIF-1α and HIF-2α in hepatocellular carcinoma with capsular invasion, portal vein tumor thrombi and patients' clinical outcome.
Yang SL; Liu LP; Jiang JX; Xiong ZF; He QJ; Wu C
Jpn J Clin Oncol; 2014 Feb; 44(2):159-67. PubMed ID: 24374892
[TBL] [Abstract][Full Text] [Related]
36. Nuclear expression of hypoxia-inducible factor-1alpha in clear cell renal cell carcinoma is involved in tumor progression.
Di Cristofano C; Minervini A; Menicagli M; Salinitri G; Bertacca G; Pefanis G; Masieri L; Lessi F; Collecchi P; Minervini R; Carini M; Bevilacqua G; Cavazzana A
Am J Surg Pathol; 2007 Dec; 31(12):1875-81. PubMed ID: 18043042
[TBL] [Abstract][Full Text] [Related]
37. The two glycolytic markers GLUT1 and MCT1 correlate with tumor grade and survival in clear-cell renal cell carcinoma.
Ambrosetti D; Dufies M; Dadone B; Durand M; Borchiellini D; Amiel J; Pouyssegur J; Rioux-Leclercq N; Pages G; Burel-Vandenbos F; Mazure NM
PLoS One; 2018; 13(2):e0193477. PubMed ID: 29481555
[TBL] [Abstract][Full Text] [Related]
38. Hypoxia-inducible factor 1alpha expression in renal cell carcinoma analyzed by tissue microarray.
Lidgren A; Hedberg Y; Grankvist K; Rasmuson T; Bergh A; Ljungberg B
Eur Urol; 2006 Dec; 50(6):1272-7. PubMed ID: 16814458
[TBL] [Abstract][Full Text] [Related]
39. Hypoxia inducible factor 1α and hypoxia inducible factor 2α play distinct and functionally overlapping roles in oral squamous cell carcinoma.
Zhu GQ; Tang YL; Li L; Zheng M; Jiang J; Li XY; Chen SX; Liang XH
Clin Cancer Res; 2010 Oct; 16(19):4732-41. PubMed ID: 20807755
[TBL] [Abstract][Full Text] [Related]
40. Emetine promotes von Hippel-Lindau-independent degradation of hypoxia-inducible factor-2α in clear cell renal carcinoma.
Kong HS; Lee S; Beebe K; Scroggins B; Gupta G; Lee MJ; Jung YJ; Trepel J; Neckers L
Mol Pharmacol; 2010 Dec; 78(6):1072-8. PubMed ID: 20813864
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
